Bacterial Infections  >>  AERAS-404  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AERAS-404 / Sanofi
NCT02066428: A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Completed
1
64
Europe
AERAS-404, H4, Placebo, Tris Buffered saline
Aeras, Statens Serum Institut
Tuberculosis
05/09
05/09
NCT02074956: A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Completed
1
60
Europe
AERAS-404, H4, Placebo, Sterile Buffer
Aeras, Statens Serum Institut
Tuberculosis
10/09
10/09
C-011-404, NCT02109874: A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404

Completed
1
40
RoW
AERAS-404 (mcg H4/nmol IC31), H4, AERAS-404, Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
Aeras, Statens Serum Institut
Tuberculosis
12/10
09/12
C-013-404, NCT02420444: A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults

Completed
1
70
Europe
BCG SSI, BCG Vaccine SSI Danish, bacillus Calmette-Guérin, Placebo, Sterile buffered saline, AERAS-404, H4:IC31
Aeras, Sanofi Pasteur, a Sanofi Company
Tuberculosis
05/12
11/13

Download Options